BR9714967A - Composições farmacêuticas aperfeiçoadas - Google Patents

Composições farmacêuticas aperfeiçoadas

Info

Publication number
BR9714967A
BR9714967A BR9714967-5A BR9714967A BR9714967A BR 9714967 A BR9714967 A BR 9714967A BR 9714967 A BR9714967 A BR 9714967A BR 9714967 A BR9714967 A BR 9714967A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
improved
ceftiofuro
enhanced pharmaceutical
resuspendability
Prior art date
Application number
BR9714967-5A
Other languages
English (en)
Other versions
BR9714967B1 (pt
Inventor
Todd P Foster
David L Kiefer
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25194373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9714967(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9714967A publication Critical patent/BR9714967A/pt
Publication of BR9714967B1 publication Critical patent/BR9714967B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS APERFEIçOADAS. A presente invenção fornece a inclusão de pequenas quantidades de água em suspensões de óleo de drogas ativas, tais como ceftiofuro de fórmula (II), particularmente o sal dr hidroclordido de ceftiofuro. As suspensões resultantes apresentam resuspendabilidade aperfeiçoada. Resuspendabilidade aperfeiçoada resulta em um produto aperfeiçoado devido a menos agitação da suspensão ser requerida antes da dosagem.
BRPI9714967-5A 1996-12-09 1997-12-03 composição farmacêutica a base de ceftiofur. BR9714967B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/806,584 US5736151A (en) 1996-12-09 1996-12-09 Antibiotic oil suspensions
PCT/US1997/021401 WO1998025621A1 (en) 1996-12-09 1997-12-03 Improved pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR9714967A true BR9714967A (pt) 2001-10-30
BR9714967B1 BR9714967B1 (pt) 2010-06-29

Family

ID=25194373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9714967-5A BR9714967B1 (pt) 1996-12-09 1997-12-03 composição farmacêutica a base de ceftiofur.

Country Status (22)

Country Link
US (1) US5736151A (pt)
EP (1) EP0941095B1 (pt)
JP (1) JP2001505910A (pt)
KR (1) KR100544248B1 (pt)
CN (1) CN100413506C (pt)
AT (1) ATE264681T1 (pt)
AU (1) AU746666B2 (pt)
BR (1) BR9714967B1 (pt)
CA (1) CA2269682C (pt)
CZ (1) CZ297632B6 (pt)
DE (1) DE69728783T2 (pt)
DK (1) DK0941095T3 (pt)
ES (1) ES2218705T3 (pt)
FI (1) FI991302A (pt)
HK (1) HK1023292A1 (pt)
HU (1) HUP0000564A3 (pt)
NO (1) NO325475B1 (pt)
NZ (1) NZ336183A (pt)
PL (1) PL190662B1 (pt)
PT (1) PT941095E (pt)
SK (1) SK72399A3 (pt)
WO (1) WO1998025621A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1317256E (pt) * 2000-09-12 2008-12-17 Pharmacia & Upjohn Co Llc Composição farmacêutica com veículo modificado
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
AU2002328168B2 (en) * 2002-08-07 2008-08-21 Merial Ltd. Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
ES2270361T3 (es) * 2003-03-20 2007-04-01 Pharmacia Corporation Formulacion dispersable de un agente antiinflamatorio.
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
MXPA06001192A (es) * 2003-07-31 2006-04-11 Pharmacia & Upjohn Co Llc Composicion farmaceutica dispersable para el tratamiento de mastitis y trastornos oticos.
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CZ300424B6 (cs) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300590B6 (cs) * 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
BRPI0922041A8 (pt) 2008-11-19 2022-08-16 Merial Ltd Formulações compreendendo ceftiofur e cetoprofeno ou cetiofur e álcool benzílico.
MY172561A (en) 2012-07-17 2019-12-03 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
FR3000392B1 (fr) 2012-12-27 2015-03-27 Virbac Nouvelles compositions pharmaceutiques veterinaires et leur procede de preparation
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
SG10202103552XA (en) 2015-03-09 2021-05-28 Intekrin Therapeutics Inc Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10420776B2 (en) * 2016-10-13 2019-09-24 RhinoNase, Inc. Antibiotic compositions for nasal irrigation and methods
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914894A (en) * 1960-08-12 1963-01-09 Beecham Res Lab Injectable pharmaceutical media
NL260648A (pt) * 1961-01-31
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
EP0233255B1 (en) * 1985-08-12 1996-05-29 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
US5223496A (en) * 1987-11-10 1993-06-29 The Upjohn Company Cephalosporin antibiotics
EP0393066B1 (en) * 1987-11-10 1994-02-02 The Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
KR920702616A (ko) * 1989-06-13 1992-10-06 원본미기재 약제를 전달하기 위한 무수 오일-기제된 액체 현탁액
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje

Also Published As

Publication number Publication date
AU5452998A (en) 1998-07-03
AU746666B2 (en) 2002-05-02
NO992780D0 (no) 1999-06-08
NO325475B1 (no) 2008-05-13
CA2269682C (en) 2009-04-14
DE69728783T2 (de) 2005-03-31
CZ297632B6 (cs) 2007-02-14
WO1998025621A1 (en) 1998-06-18
PL190662B1 (pl) 2005-12-30
CA2269682A1 (en) 1998-06-18
DE69728783D1 (de) 2004-05-27
ES2218705T3 (es) 2004-11-16
HUP0000564A3 (en) 2001-01-29
SK72399A3 (en) 2000-05-16
KR20000069360A (ko) 2000-11-25
KR100544248B1 (ko) 2006-01-23
CN100413506C (zh) 2008-08-27
ATE264681T1 (de) 2004-05-15
EP0941095B1 (en) 2004-04-21
EP0941095A1 (en) 1999-09-15
CZ202599A3 (cs) 1999-09-15
HK1023292A1 (en) 2000-09-08
US5736151A (en) 1998-04-07
FI991302A0 (fi) 1999-06-08
FI991302A (fi) 1999-06-08
NZ336183A (en) 2000-12-22
BR9714967B1 (pt) 2010-06-29
CN1238690A (zh) 1999-12-15
NO992780L (no) 1999-06-08
HUP0000564A2 (hu) 2000-10-28
DK0941095T3 (da) 2004-08-02
PT941095E (pt) 2004-08-31
JP2001505910A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
BR9714967A (pt) Composições farmacêuticas aperfeiçoadas
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
DE69531502D1 (de) Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
BR9913512A (pt) Derivados de 4,4-biarilpiperidina com atividade de receptor de opióide
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
EA199901015A1 (ru) 4"-замещенные производные 9-деоксо-9а-а3а-9а-гомоэритромицина а
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
EA200100623A1 (ru) Кетолидные антибиотики
EA200100774A1 (ru) Гетероциклические производные с функциональными группами (варианты), фармацевтическая композиция и комбинация, способ модулирования активности рецептора хемокина (варианты), способ профилактики инфицирования вич и лечения инфекции вич, замедления проявления спид и лечения спид, способ лечения воспалительных процессов
BR9916680A (pt) Derivados da 3,3-biarilpiperidina e2,2-biarilmorfolina
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
ATE317846T1 (de) Phosphoramidat-prodrugs
NO20010940L (no) TAN-1057 derivater
EA200101241A1 (ru) Производные индола
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
TNSN99146A1 (fr) Derives de 1-heteroaryl-pyrrolidine, -piperidine et - homopiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0008511A (pt) Sistemas tiazol policìclicos e seu emprego como anoréticos contendo estes compostos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/06/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: PHARMACIA AND UPJOHN COMPANY LLC (US)

B25A Requested transfer of rights approved

Owner name: PAH PANDU LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS PANDU LLC (US)

B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29.06.2020